Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8253086 | 0.80 | TSHR (0.37) | LMNABLM | |
| SCHEMBL30185335 | 0.79 | CHRM3 (0.41) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL8254088 | 0.78 | FFAR3 (0.38) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL8253101 | 0.78 | CHRM3 (0.37) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL8401863 | 0.73 | CHRM3 (0.36) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL30185334 | 0.73 | CHRM3 (0.39) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL16875459 | 0.71 | CHRM3 (0.34) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL28563747 | 0.71 | CHRM3 (0.34) | CHRM3LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL43992 | 0.71 | — | — | |
| SCHEMBL12515641 | 0.70 | PTPN1 (0.35) | CHRM3LMNACHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | CHRM3 4323/4885LMNA 2387/4885CHRM2 4781/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CHRM3 4323/4885LMNA 2387/4885CHRM2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.